Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T.

Mol Oncol. 2007 Sep;1(2):160-71. doi: 10.1016/j.molonc.2007.03.004. Epub 2007 Apr 4. Erratum in: Mol Oncol. 2010 Apr;4(2):169.

2.

Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.

Schindlbeck C, Kampik T, Janni W, Rack B, Jeschke U, Krajewski S, Sommer H, Friese K.

Breast Cancer Res. 2005;7(6):R1174-85. Epub 2005 Nov 24.

3.

Molecular signature associated with bone marrow micrometastasis in human breast cancer.

Woelfle U, Cloos J, Sauter G, Riethdorf L, Jänicke F, van Diest P, Brakenhoff R, Pantel K.

Cancer Res. 2003 Sep 15;63(18):5679-84.

4.

Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer.

Bidard FC, Kirova YM, Vincent-Salomon A, Alran S, de Rycke Y, Sigal-Zafrani B, Sastre-Garau X, Mignot L, Fourquet A, Pierga JY.

Ann Oncol. 2009 Nov;20(11):1836-41. doi: 10.1093/annonc/mdp200. Epub 2009 Jun 25.

5.

Micrometastasis in breast cancer and other solid tumors.

Pantel K, Woelfle U.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):120-5. Review.

PMID:
15471214
7.

[Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].

Liersch T, Gatzemeier W, Scharnberg P, Jürgens B, Wörmann B, Becker H, Rauschecker HF, Hiddemann W, Wulf GG.

Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):277-80. German.

PMID:
14518259
8.
9.

Expression of heterochromatin protein 1 in the primary tumor of breast cancer patients in the presence or absence of occult metastatic cells in the bone marrow.

Abreu AP, Milani C, Katayama ML, Barbosa KC, Gomes da Fonseca L, Goes JC, Brentani MM, Koike Folgueira MA.

Int J Biol Markers. 2008 Oct-Dec;23(4):219-24.

PMID:
19199269
10.

Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.

Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY; Institut Curie Breast Cancer Study Group.

Clin Cancer Res. 2008 Jun 1;14(11):3306-11. doi: 10.1158/1078-0432.CCR-07-4749.

11.

Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study.

Valladares-Ayerbes M, Iglesias-Díaz P, Díaz-Prado S, Ayude D, Medina V, Haz M, Reboredo M, Antolín S, Calvo L, Antón-Aparicio LM.

J Cancer Res Clin Oncol. 2009 Sep;135(9):1185-95. doi: 10.1007/s00432-009-0559-7. Epub 2009 Feb 17.

PMID:
19221791
12.

ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.

Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmüller G, Pantel K.

Cancer Res. 2001 Mar 1;61(5):1890-5.

13.

Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.

Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR.

J Natl Cancer Inst. 2005 Dec 21;97(24):1840-7.

14.

Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse.

Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Rodrigues M, Diéras V, Mignot L, Sastre-Garau X, Poupon MF, Pierga JY.

Clin Exp Metastasis. 2008;25(8):871-5. doi: 10.1007/s10585-008-9203-1. Epub 2008 Nov 7.

PMID:
18989740
15.

A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow.

Tjensvoll K, Gilje B, Oltedal S, Shammas VF, Kvaløy JT, Heikkilä R, Nordgård O.

Breast Cancer Res Treat. 2009 Jul;116(2):329-38. doi: 10.1007/s10549-008-0204-1. Epub 2008 Oct 10.

PMID:
18846421
16.

Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.

Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Krajewski S, Sommer H, Friese K.

Breast Cancer Res Treat. 2007 Jan;101(1):17-25. Epub 2006 Jun 29.

PMID:
16807671
17.

Subtypes of breast cancer show preferential site of relapse.

Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW.

Cancer Res. 2008 May 1;68(9):3108-14. doi: 10.1158/0008-5472.CAN-07-5644.

18.

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

Breast Cancer Res. 2008;10(5):R86. doi: 10.1186/bcr2156. Epub 2008 Oct 16.

19.

Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.

Bregni M, Fleischhauer K, Bernardi M, Pescarollo A, Guggiari E, Lunghi F, Deola S, Scaramuzza S, Re F, Setola E, Monari M, Mazzi B, Servida P, Corradini P, Peccatori J.

Bone Marrow Transplant. 2006 Feb;37(3):311-5.

PMID:
16400340
20.

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G.

J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8.

Items per page

Supplemental Content

Write to the Help Desk